January 4, 2019January 4, 2019

Abivax to Present Results of Trials of ABX464 as Ulcerative Colitis Therapy

News

Abivax will present the complete results of its Phase 2a trial ABX464-101 (NCT03093259) and interim results of the open-label extension study ABX464-102 (NCT03368118). Both aimed to assess the safety and efficacy of ABX464 as a treatment ... Read more

September 5, 2018September 5, 2018

Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial

News

Abivax‘s small, anti-inflammatory molecule ABX464 significantly increased clinical remission and mucosal healing over placebo in patients with moderate to severe active ulcerative colitis resistant to other therapies, top-line results from a ... Read more